Restoring and preserving high-acuity hearing is one of the greatest unmet challenges of medicine: 360 million people worldwide have disabling hearing loss, but there are no FDA-approved therapies to address it. [more information]
Alkahest is a clinical stage biopharmaceutical company dedicated to treating neurodegenerative and age-related diseases with transformative therapies targeting the aging plasma proteome. Alkahest is developing novel plasma-based therapies in collaboration with Grifols, a global healthcare company and leading producer of plasma therapies. [more information]
Alloplex Biotherapeutics, Inc.
Our lead oncology program uses proprietary leukocyte activator cell (LAC) lines, which are engineered from a parental tumor cell line, to specifically engage and activate peripheral blood mononuclear cells (PBMC) through through native receptors. [more information]
Treating sepsis associated acute kidney injury (AKI) with proprietary recombinant alkaline phosphatase (recAP). Results from Ph 2 trial in 300+ pts, demonstrated relative improvement of 40%+ OS in recAP group. Initiating pivotal Ph 3 in SA-AKI patients in Q1 20 (P endpoint: Day 28 all-cause mortality). First interim analysis exp Q1 2021. [more information]
Phase 3 ready, Teverelix, a long acting injectable peptide GnRH antagonist. Lead indication for prostate cancer, followed by benign prostatic hyperplasia (BPH), acute urinary retention (AUR), uterine fibroids and endometriosis. Over 450 subjects have been dosed over 850 times to date with no serious adverse reactions and good local tolerance. [more information]
CD40 agonist mAb; 170+ pts dosed (mono & combi settings). 7 ongoing Ph 2s, undisclosed ocular disease program in Ph 3. AACR: Ph 1b data (w/Parker Inst); collabs w/BMY, MDACC, Yale, et al [more information]
Current engineered immune cell therapies often target tumors through a mono-specific receptor that is constitutively expressed and active. In contrast, Arcellx has developed Antigen Receptor Complex T cells (ARC-T) that are readily silenced, activated, and reprogrammed in vivo by administration of a tumor-targeting antigen protein called a sparX. [more information]
Axial Biotherapeutics, Inc.
Axial Biotherapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. [more information]
Cadent Therapeutics is creating breakthrough therapies for the treatment of movement disorders and cognitive impairment. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 1 clinical studies for the treatment of treatment resistant depression. [more information]
Checkmate’s lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to PD-1 therapy in some patients. [more information]
Chondrial Therapeutics is an emerging biotechnology company focused on the treatment of rare mitochondrial diseases. Chondrial’s lead compound is CTI-1601, which the Company is developing as a potential treatment for Friedreich’s Ataxia. [more information]
Confo Therapeutics is a pioneering biopharmaceutical company building a portfolio of best-in-class small molecule medicines for the treatment of orphan and rare diseases using its proprietary Confo® technology, a proprietary GPCR conformation-sensitive drug discovery engine. [more information]
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. [more information]
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. [more information]
Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space. [more information]
Impact Therapeutics Inc
Based in China, IMPACT is committed to the discovery and development of best-in-class therapeutics to treat cancer and other life-threatening diseases. IMPACT is a clinical-stage company with a unique small-molecule drug discovery and development platform targeting DDR. IMPACT's leading program, PARP inhibitor IMP4297, is currently undergoing phase I trials in Australia and China. [more information]
iTeos Therapeutics SA
iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company advanced EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in January 2019. [more information]
Kineta (Private) - wholly owned preclinical anti-VISTA (innate immune target) antibody reprograms the tumor microenvironment and is differentiated from other immunotherapies by blocking suppressive cells in cold tumors. $520M deal with Pfizer for its small molecule RIG-I immunotherapy and $360M+ deal with Genentech for KCP506, preclinical, non-opioid for chronic pain. [more information]
Klox Technologies, Inc.
Proprietary biophotonic system utilizes multi-LED array and chromophore converter gel to promote skin repair. Acne & skin rejuvenation indication approved in EU and Canada, ongoing trials in wound healing. [more information]
Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. [more information]
Oral PPARγ agonist, MIN-102, in Pivotal Ph 2/3 for X-linked ALD and Ph 2 Friedrich’s Ataxia; data for both expected by end of 2020. VC investors include Kurma, Ysios, Fund+, Roche, Idinvest, etc [more information]
The primary objective of the study was to assess the efficacy of various daily doses of tolperisone to determine the dose to be used for the planned Phase 3 clinical program. Given the positive results of the STAR Study, Neurana plans to conduct an end-of-Phase 2 meeting with the FDA in the first quarter of 2020 and initiate Phase 3 clinical studies of tolperisone later in 2020. [more information]
Developer of cancer therapies intended to improve long-term survival of cancer patients worldwide. The company's therapy offers immune-modulatory monoclonal antibody combined with immune checkpoint inhibitors, enabling medical companies to improve patients health. [more information]
A biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants. [more information]
The company’s lead candidate, REX-001, is a highly innovative autologous cell therapy that is being studied in a Phase III clinical program in patients with critical limb ischemia (CLI) with diabetes, a poorly treated disease with a high risk of amputation and death. [more information]
The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS301, its clinical stage cancer vaccine, and SNS-723, its cell therapy program in preclinical development for solid tumors and hematological cancers. [more information]
Sigilon Therapeutics, Inc.
Platform cell therapy company focusing on several chronic diseases (hemophilia, T1D, lysosomal storage disorders); 5 INDs exp in the next 2 years; 1st IND in Jan 2020 (Hemophilia A). Eli Lilly collaboration in T1D ($75m initial commitment, $410 milestones & single to double digit royalties). Engineering cells to produce crucial proteins/enzymes/etc; encapsulate cells in alginate sphere covalently bonded w/coating that prevents fibrosis & rejection; coating dev'd at Bob Langer's Lab at MIT. Flagship Pioneeri [more information]
With almost two decades of experience in the biotechnology, pharmaceutical, medical technology and life science technology sectors, the Trout Group offers its clients the knowledge base needed to clarify investment themes and leverage key relationships for increased exposure to the proper audience. [more information]
Sonnet Biotherapeutics, Inc.
Sonnet's interleukin-based candidate has been shown to enhance pK (up to 10 fold) and improve tumor delivery with an increase in in vivo efficacy (30 fold) as demonstrated in a mice tumor model. The Sonnet platform de-risks the use of interleukins by greatly extending their in vivo half-life, while also improving their specificity to tumor tissue. [more information]
By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna currently has four programs in phase 2 development. [more information]
is discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors. PEN-221 is a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors. [more information]
Our exosomes are prepared to specifically target cancer cells and deliver their genetic payloads to effect maximum disruption on cancer growth. We produce specialized types of exosomes that are selectively taken up by cancer cells and can be used to deliver tumor suppressive miRNAs and other disruptive molecules to cancer cells with minimal effects on normal tissue. [more information]
Tempest Therapeutics is a development‐stage biotechnology company advancing small molecules that modulate anti‐tumor immunity pathways. The company has a balanced and deep pipeline consisting of first‐in‐class and potential best‐in‐class small molecule therapeutics that modulate distinct immune response pathways relevant to mounting an effective anti‐tumor response. [more information]
Bispecific Abs: dual angiogenesis inhibitor (TR009) and 3 immunomodulatory dual checkpoint & T cell engaging BsAbs. ASCO TR009 P1a results. Interim P1a dose escalation: clin benefit of 66%, one PR (7.5mg) no DLTs in solid tumors [more information]
T cell immunotherapies for infectious diseases (ID) and cancer via CD8+ T cell induction – spinout from Jenner Institute. ChAdOx (prime) and MVA (boost) pipeline including pivotal Ph2b for flu prophylactic in Q1 2020 and Ph1/2 POC for HPV and HBV immunotherapies by Q1 2021, two cancer immunotherapy programs (personalized vaccine and MAGE-NYESO therapeutics) entering clinic in 2020. [more information]
Viracta Therapeutics, Inc.
Viracta is a clinical-stage drug development company focused on advancing novel epigenetic therapeutics derived from its proprietary Kick & Kill therapeutic approach to benefit patients with viral-associated cancers and other serious diseases. Viracta plans to enter into additional geographic and combination therapy partnerships. [more information]
Vyome Therapeutics Inc.
$22M fund raise Jan '19. Advanced lead asset VB-1953 to Ph 2 for moderate to severe acne. Pipeline DART - dual action overcoming antimicrobial resistance - and MRT - patented antifungal platform. Treat drug-resistant skin pathogens. [more information]
T-Guard has been granted FDA Fast Track Designation for the treatment of steroid-refractory acute Graft-versus-Host Disease (SR-aGVHD), and is entering pivotal Ph3 studies in the U.S. Xenikos is headquartered in the Netherlands, has established a subsidiary at the East Coast US to pursue a go-it-alone strategy in the US. [more information]
Devl biotherapeutics for cancers and infectious disease. Products in devt include Ph 1 IO product targeting solid tumors Ph 3 PIKA vaccine targeting hep B and rabies infections. [more information]